Zenas BioPharma, Inc.
NASDAQ:ZBIOBiotechnology
+$0.64 today
- Market cap
- $1.79B
- Beta
- -0.69
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$7.64
Volume 0.48M
Average 0.71M
ZBIO Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Zenas BioPharma, Inc.NASDAQ: ZBIO
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $433.48M rose 437757.6% year over year, ahead of the +56.8% change in trailing-twelve-month financing cash flow. Sequentially, it rose 207.8% from the prior quarter. Over 3 fiscal years it compounded at +53.6% a year.
Context
- Financing cash flow amounted to 2152.8% of revenue in FY2025, down 6106.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +437757.6% holds above the trailing-twelve-month pace of +56.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 215.28M USD
- Year-over-year change
- -47.9%
- 3-year CAGR
- +53.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 215.28M | -47.9% |
| FY2024 | 2024-12-31 | 412.96M | +1952.9% |
| FY2023 | 2023-12-31 | 20.12M | -66.1% |
| FY2022 | 2022-12-31 | 59.39M | — |
Financing Cash Flow vs competitors
How ZBIO compares with its peers on the latest reported figures
- ZBIO's LTM Mar 2026 financing cash flow of $648.66M is the largest of the 8 companies compared; the peer median is $30.01M.
- Its year-over-year change of +56.8% is the 3rd highest of 8, against a peer median of +10.0%.
- Over three fiscal years its annual growth of +53.6% compares with a peer median of -4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $648.66M | +56.8% | +53.6% | — | |
| LTM Sep 2026 | $596.22M | +24.1% | +103.3% | 8403.4% | |
| LTM Mar 2026 | $141.69M | +10.0% | -4.0% | — | |
| LTM Mar 2026 | $52.19M | -29.8% | — | 623.8% | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $30.01M | -74.5% | — | — |
| FY2025 | $10.01M | +178.0% | — | — | |
| LTM Mar 2026 | $5.67M | +234.8% | — | 10.6% | |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $3.07M | -99.2% | -37.4% | 92.5% |
| Peer median (excluding ZBIO) | $30.01M | +10.0% | -4.0% | 358.2% | |
Competitors are the stored peer set for ZBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (119.28M) | (37.12M) | (156.99M) | (377.74M) |
| Depreciation & Amortization | 78K | 113K | 137K | (1.88M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 737K | 3.5M | 10.82M | 26.35M |
| Change in Working Capital | 7.97M | (8.04M) | 25.43M | 951K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.09M | (418K) | 11.74M | (10.04M) |
| Other Working Capital | 6.88M | (7.62M) | 13.69M | 10.99M |
| Other Non-Cash Items | 44.85M | 11.03M | 925K | 179.98M |
| Operating Cash Flow | (65.65M) | (30.53M) | (119.67M) | (172.33M) |
| Capital Expenditures | (2.2M) | (17K) | (131K) | (18K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (36.42M) | (417.76M) |
| Sales of Investments | 0 | 0 | 6M | 200.89M |
| Other Investing Activities | (2M) | 0 | 0 | (35M) |
| Investing Cash Flow | (2.2M) | (17K) | (30.55M) | (251.89M) |
| Debt Repayment | 0 | 20M | 0 | 0 |
| Common Stock Issued | 59.39M | 116K | 240.64M | 152.95M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | (6.06M) | 62.34M |
| Financing Cash Flow | 59.39M | 20.12M | 412.96M | 215.28M |
| Effect of Forex Changes | (41K) | 78K | 157K | (252K) |
| Net Change in Cash | (8.5M) | (10.35M) | 262.89M | (209.19M) |
| Free Cash Flow | (67.85M) | (30.55M) | (119.81M) | (172.35M) |
Zenas BioPharma, Inc.
NASDAQ:ZBIO
Intrinsic Alpha fair value
Locked
Current Price
$26.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.